BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 32234712)

  • 21. Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis.
    Santo T; Clark B; Hickman M; Grebely J; Campbell G; Sordo L; Chen A; Tran LT; Bharat C; Padmanathan P; Cousins G; Dupouy J; Kelty E; Muga R; Nosyk B; Min J; Pavarin R; Farrell M; Degenhardt L
    JAMA Psychiatry; 2021 Sep; 78(9):979-993. PubMed ID: 34076676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modelling the combined impact of interventions in averting deaths during a synthetic-opioid overdose epidemic.
    Irvine MA; Kuo M; Buxton JA; Balshaw R; Otterstatter M; Macdougall L; Milloy MJ; Bharmal A; Henry B; Tyndall M; Coombs D; Gilbert M
    Addiction; 2019 Sep; 114(9):1602-1613. PubMed ID: 31166621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Opioid agonist treatment uptake within provincial correctional facilities in British Columbia, Canada.
    Kurz M; Dale LM; Min JE; Hongdilokkul N; Greiner L; Olley M; McLeod KE; Slaunwhite A; Nosyk B
    Addiction; 2022 May; 117(5):1353-1362. PubMed ID: 34729848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved.
    Degenhardt L; Randall D; Hall W; Law M; Butler T; Burns L
    Drug Alcohol Depend; 2009 Nov; 105(1-2):9-15. PubMed ID: 19608355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Buprenorphine/naloxone associated with a reduced odds of fentanyl exposure among a cohort of people who use drugs in Vancouver, Canada.
    Young S; Hayashi K; Grant C; Milloy MJ; DeBeck K; Wood E; Fairbairn N
    Drug Alcohol Depend; 2021 Nov; 228():109006. PubMed ID: 34509737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
    Geddes L; Iversen J; Wand H; Maher L
    Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Navigating Opioid Agonist Therapy among Young People who use Illicit Opioids in Vancouver, Canada.
    Pilarinos A; Kwa Y; Joe R; Thulien M; Buxton JA; DeBeck K; Fast D
    Int J Drug Policy; 2022 Sep; 107():103773. PubMed ID: 35780565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Willingness to take buprenorphine/naloxone among people who use opioids in Vancouver, Canada.
    Weicker SA; Hayashi K; Grant C; Milloy MJ; Wood E; Kerr T
    Drug Alcohol Depend; 2019 Dec; 205():107672. PubMed ID: 31706251
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concurrent drug injection during opioid agonist treatment among people who inject drugs in Ukraine.
    Makarenko I; Mazhnaya A; Marcus R; Pykalo I; Madden L; Filippovich S; Dvoriak S; Altice FL
    J Subst Abuse Treat; 2018 Apr; 87():1-8. PubMed ID: 29471921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Self-harm and suicide during and after opioid agonist treatment among primary care patients in England: a cohort study.
    Padmanathan P; Forbes H; Redaniel MT; Gunnell D; Lewer D; Moran P; Watson B; Degenhardt L; Hickman M
    Lancet Psychiatry; 2022 Feb; 9(2):151-159. PubMed ID: 34921800
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?
    Srivastava A; Kahan M; Nader M
    Can Fam Physician; 2017 Mar; 63(3):200-205. PubMed ID: 28292795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Naloxone prescriptions among patients with a substance use disorder and a positive fentanyl urine drug screen presenting to the emergency department.
    Ali SA; Shell J; Harris R; Bedder M
    Harm Reduct J; 2023 Oct; 20(1):144. PubMed ID: 37798673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amount of naloxone used to reverse opioid overdoses outside of medical practice in a city with increasing illicitly manufactured fentanyl in illicit drug supply.
    Bell A; Bennett AS; Jones TS; Doe-Simkins M; Williams LD
    Subst Abus; 2019; 40(1):52-55. PubMed ID: 29558283
    [No Abstract]   [Full Text] [Related]  

  • 34. Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone.
    Rolland B; Trojak B; Nourredine M; Bachellier J; Chappuy M; Bendimerad P; Kosim M; Hjelmström P; Meroueh F; Nubukpo P; Brousse G
    Drug Alcohol Depend; 2021 Mar; 220():108492. PubMed ID: 33482572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prepacked naloxone administration for suspected opioid overdose in the era of illicitly manufactured fentanyl: a retrospective study of regional poison center data.
    Mahonski SG; Leonard JB; Gatz JD; Seung H; Haas EE; Kim HK
    Clin Toxicol (Phila); 2020 Feb; 58(2):117-123. PubMed ID: 31092050
    [No Abstract]   [Full Text] [Related]  

  • 36. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.
    Sordo L; Barrio G; Bravo MJ; Indave BI; Degenhardt L; Wiessing L; Ferri M; Pastor-Barriuso R
    BMJ; 2017 Apr; 357():j1550. PubMed ID: 28446428
    [No Abstract]   [Full Text] [Related]  

  • 37. Development and validation of health system performance measures for opioid use disorder in British Columbia, Canada.
    Nosyk B; Min JE; Pearce LA; Zhou H; Homayra F; Wang L; Piske M; McCarty D; Gardner G; O'Briain W; Wood E; Daly P; Walsh T; Henry B
    Drug Alcohol Depend; 2022 Apr; 233():109375. PubMed ID: 35231716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trends in engagement in the cascade of care for opioid use disorder, Vancouver, Canada, 2006-2016.
    Socías ME; Wood E; Kerr T; Nolan S; Hayashi K; Nosova E; Montaner J; Milloy MJ
    Drug Alcohol Depend; 2018 Aug; 189():90-95. PubMed ID: 29894910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder.
    Bishop B; Gilmour J; Deering D
    Int J Ment Health Nurs; 2019 Feb; 28(1):226-236. PubMed ID: 30019812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exposure to opioid maintenance treatment reduces long-term mortality.
    Gibson A; Degenhardt L; Mattick RP; Ali R; White J; O'Brien S
    Addiction; 2008 Mar; 103(3):462-8. PubMed ID: 18190664
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.